CN101918404A - 4-(吡咯并[2，3-c]吡啶-3-基)-嘧啶-2-胺衍生物 - Google Patents

4-(吡咯并[2，3-c]吡啶-3-基)-嘧啶-2-胺衍生物 Download PDF

Info

Publication number
CN101918404A
CN101918404A CN200880125171XA CN200880125171A CN101918404A CN 101918404 A CN101918404 A CN 101918404A CN 200880125171X A CN200880125171X A CN 200880125171XA CN 200880125171 A CN200880125171 A CN 200880125171A CN 101918404 A CN101918404 A CN 101918404A
Authority
CN
China
Prior art keywords
compound
formula
expression
acceptable salt
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880125171XA
Other languages
English (en)
Chinese (zh)
Inventor
D·多施
C·西伦贝格
T·J·J·穆勒
E·莫库尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN101918404A publication Critical patent/CN101918404A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880125171XA 2008-01-22 2008-12-23 4-(吡咯并[2，3-c]吡啶-3-基)-嘧啶-2-胺衍生物 Pending CN101918404A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008005493.3 2008-01-22
DE102008005493A DE102008005493A1 (de) 2008-01-22 2008-01-22 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
PCT/EP2008/011098 WO2009092431A1 (de) 2008-01-22 2008-12-23 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidin-2-amin-derivative

Publications (1)

Publication Number Publication Date
CN101918404A true CN101918404A (zh) 2010-12-15

Family

ID=40386204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880125171XA Pending CN101918404A (zh) 2008-01-22 2008-12-23 4-(吡咯并[2，3-c]吡啶-3-基)-嘧啶-2-胺衍生物

Country Status (14)

Country Link
US (1) US20100292262A1 (enExample)
EP (1) EP2231664A1 (enExample)
JP (1) JP5524864B2 (enExample)
KR (1) KR20100112626A (enExample)
CN (1) CN101918404A (enExample)
AR (1) AR070212A1 (enExample)
AU (1) AU2008348816B2 (enExample)
BR (1) BRPI0821936A2 (enExample)
CA (1) CA2712612A1 (enExample)
DE (1) DE102008005493A1 (enExample)
IL (1) IL206905A0 (enExample)
MX (1) MX2010007927A (enExample)
WO (1) WO2009092431A1 (enExample)
ZA (1) ZA201005959B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683166A (zh) * 2013-08-30 2016-06-15 Ptc医疗公司 取代的嘧啶Bmi-1抑制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
JP2014515368A (ja) 2011-05-26 2014-06-30 第一三共株式会社 プロテインキナーゼ阻害剤としての複素環化合物
DK2922828T3 (da) 2012-11-21 2020-08-31 Ptc Therapeutics Inc 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN107074882B (zh) 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的吡唑并嘧啶衍生物
KR102500071B1 (ko) 2014-10-23 2023-02-14 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 화합물
ES2704749T3 (es) 2014-10-23 2019-03-19 Janssen Pharmaceutica Nv Nuevos derivados de pirazol en calidad de inhibidores de nik
EA033238B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные тиенопиримидина в качестве ингибиторов nik
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR20080063809A (ko) * 2005-09-30 2008-07-07 버텍스 파마슈티칼스 인코포레이티드 야누스 키나아제의 억제제로서 유용한 데아자퓨린
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683166A (zh) * 2013-08-30 2016-06-15 Ptc医疗公司 取代的嘧啶Bmi-1抑制剂
CN105683166B (zh) * 2013-08-30 2020-06-16 Ptc医疗公司 取代的嘧啶Bmi-1抑制剂

Also Published As

Publication number Publication date
JP5524864B2 (ja) 2014-06-18
AR070212A1 (es) 2010-03-25
IL206905A0 (en) 2010-12-30
JP2011510028A (ja) 2011-03-31
ZA201005959B (en) 2011-04-28
WO2009092431A1 (de) 2009-07-30
EP2231664A1 (de) 2010-09-29
CA2712612A1 (en) 2009-07-30
KR20100112626A (ko) 2010-10-19
DE102008005493A8 (de) 2010-03-25
AU2008348816A1 (en) 2009-07-30
AU2008348816B2 (en) 2011-10-20
BRPI0821936A2 (pt) 2015-06-16
DE102008005493A1 (de) 2009-07-23
MX2010007927A (es) 2010-08-09
US20100292262A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
JP5411849B2 (ja) ６−（ピロロピリジニル）−ピリミジン−２−イルアミン誘導体ならびに癌およびａｉｄｓの処置のためのその使用
JP5524864B2 (ja) ４−（ピロロ［２，３−ｃ］ピリジン−３−イル）ピリミジン−２−アミン誘導体
JP5891249B2 (ja) ７−アザインドール誘導体
JP5731481B2 (ja) ３−（１，２，３−トリアゾール−４−イル）ピロロ［２，３−ｂ］ピリジン誘導体
JP5891233B2 (ja) ７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体
CN102056926A (zh) 吡咯并吡啶基嘧啶-2-基胺衍生物
JP2009530321A (ja) ４−（ピロロピリジニル）ピリミジニル−２−アミン誘導体
JP6074364B2 (ja) ５−（１，２，３−トリアゾール−４−イル）−７ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体
JP5718359B2 (ja) ピロロ［２，３−ｂ］ピラジン−７−イルピリミジン化合物
JP2013544264A (ja) ＰＤＫ１阻害剤としての３−ヘタリール置換ピロロ［２，３−ｂ］ピリジン誘導体
JP5508026B2 (ja) ４−（ピロロピリジニル）ピリミジン−２−イルアミン誘導体
CN103764651B (zh) 适合治疗癌症疾病的7-氮杂吲哚衍生物
HK1140203A (en) 4-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives
HK1142332A (en) 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids
HK1169118A (en) 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20101215